StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $11.39 | $10.32 | -9.39% | 2.5M |
| 05-18 | $10.38 | $10.84 | +4.43% | 2.3M |
| 05-19 | $11.04 | $11.38 | +3.08% | 2.2M |
| 05-20 | $11.40 | $11.91 | +4.47% | 2.0M |
| 05-21 | $11.69 | $12.34 | +5.56% | 1.1M |
Aggregate of 13 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows QDEL's percentile within the scored universe — observational ranking, not a recommendation.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-03 | Annual 2023 2023-12-31 | Annual 2023 2023-01-01 | Annual 2022 2022-01-02 | Annual 2021 2021-01-03 |
|---|---|---|---|---|---|
Revenue | $634.51M | $3.00B | $3.27B | $1.70B | $1.66B |
Operating Income | Not available | $139.10M | $843.70M | $906.00M | $1.06B |
Net Income | Not available | $-10.10M | $548.70M | $704.20M | $810.30M |
EPS (Diluted) | $-0.03 | $-0.15 | $9.56 | $16.43 | $18.60 |
Total Assets | Not available | $8.56B | $8.86B | $2.43B | Not available |
Total Liabilities | Not available | $3.56B | $3.92B | $501.00M | Not available |
Cash & Equivalents | Not available | $118.90M | $292.90M | $802.80M | $489.90M |
Free Cash Flow OCF − CapEx | Not available | $70.90M | $744.40M | $513.10M | $564.80M |
Shares Outstanding | Not available | 66.70M | 66.40M | 41.70M | 43.60M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
QDEL is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.